State of Alaska Department of Revenue lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 1.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 308,446 shares of the biopharmaceutical company’s stock after selling 4,655 shares during the quarter. State of Alaska Department of Revenue’s holdings in Gilead Sciences were worth $26,479,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Legacy Bridge LLC acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $30,000. JFS Wealth Advisors LLC grew its holdings in Gilead Sciences by 68.1% during the third quarter. JFS Wealth Advisors LLC now owns 400 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 162 shares during the period. Pacifica Partners Inc. grew its holdings in Gilead Sciences by 179.7% during the third quarter. Pacifica Partners Inc. now owns 414 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 266 shares during the period. Horan Securities Inc. grew its holdings in Gilead Sciences by 217.9% during the third quarter. Horan Securities Inc. now owns 461 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 316 shares during the period. Finally, EWG Elevate Inc. acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $45,000. Institutional investors and hedge funds own 78.72% of the company’s stock.
Insiders Place Their Bets
In other Gilead Sciences news, insider Merdad Parsey sold 6,126 shares of the company’s stock in a transaction on Monday, March 13th. The shares were sold at an average price of $78.99, for a total value of $483,892.74. Following the transaction, the insider now directly owns 70,130 shares in the company, valued at $5,539,568.70. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.16% of the company’s stock.
Analyst Upgrades and Downgrades
Gilead Sciences Stock Performance
NASDAQ GILD traded down $2.54 on Friday, hitting $77.31. 16,828,078 shares of the stock were exchanged, compared to its average volume of 5,303,449. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.29 and a quick ratio of 1.15. The business’s fifty day moving average is $83.20 and its 200 day moving average is $78.51. Gilead Sciences, Inc. has a 52 week low of $57.17 and a 52 week high of $89.74. The company has a market capitalization of $96.41 billion, a PE ratio of 21.18, a P/E/G ratio of 0.95 and a beta of 0.38.
Gilead Sciences (NASDAQ:GILD – Get Rating) last posted its quarterly earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.17. Gilead Sciences had a net margin of 16.83% and a return on equity of 44.46%. The firm had revenue of $7.39 billion for the quarter, compared to analyst estimates of $6.63 billion. During the same period in the prior year, the firm posted $0.69 earnings per share. The company’s quarterly revenue was up 2.0% compared to the same quarter last year. Research analysts anticipate that Gilead Sciences, Inc. will post 6.86 EPS for the current fiscal year.
Gilead Sciences Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 30th. Shareholders of record on Wednesday, March 15th will be given a dividend of $0.75 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.73. This represents a $3.00 annualized dividend and a yield of 3.88%. The ex-dividend date of this dividend is Tuesday, March 14th. Gilead Sciences’s dividend payout ratio is 82.19%.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
- Get a free copy of the StockNews.com research report on Gilead Sciences (GILD)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.